CYRX
$8.36
Cryoport, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostora...
Recent News
Cryoport, Inc. Q4 2025 Earnings Call Summary
Moby summary of Cryoport, Inc.'s Q4 2025 earnings call
CryoPort Inc (CYRX) Q4 2025 Earnings Call Highlights: Record Growth in Cell and Gene Therapy Revenue
CryoPort Inc (CYRX) surpasses revenue expectations with a 29% increase in commercial cell and gene therapy, setting a strong foundation for 2026.
CryoPort Q4 Earnings Call Highlights
CryoPort (NASDAQ:CYRX) reported fiscal 2025 results that management characterized as a year of “strong progress,” highlighted by revenue above prior guidance, continued commercial cell and gene therapy momentum, and further steps toward profitability. Fiscal 2025 results and mix For the full year,
Cryoport (CYRX) Q4 2025 Earnings Call Transcript
As a reminder, Cryoport, Inc. has uploaded their fourth quarter and full year 2025 in review document to the main page of the Cryoport, Inc. website. This document provides a review of Cryoport, Inc.'s financial and operational performance and the general business outlook. Before I turn the call over to Jerry, please note that because of the strategic partnership that has been established with DHL and the related sale of CryoPDP to DHL, CryoPDP's financials, which were previously a part of Cryoport, Inc.'s Life Sciences and Services reportable segment, are now presented as discontinued operations.
CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates
CryoPort (CYRX) delivered earnings and revenue surprises of -8.64% and +6.17%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?